Lykos… moved to patent MDMA in late 2022, filing reveals
…another big ‘if’ is whether the company will even obtain FDA approval for its MDMA-assisted therapy at all… Specifically, Lykos’ patent application claims a composition comprising a salt or solvate of MDMA along with one or more excipients, where the average particle size in the composition is, at its broadest, between 50 and 400 microns,…
Recent Comments